



# **Draft Programme**

## **Accelerating the TB vaccine pipeline – towards Horizon Europe**

**27 January – 29 January 2020**

Hotel Eurotel Victoria  
Les Diablerets  
Switzerland

## **Monday 27 January 2020**

(Eurotel Victoria)

15:00 - 18:00 TBVI R&D partner meetings

15:00 - 16:30 From TBVAC2020 to Horizon Europe (WP meetings)

16:30 - 17:00 *Break*

17:00 - 18:30 R&I group

19.30 *Dinner* (Restaurant Eurotel)

## **Tuesday 28 January 2020**

(Maison des Congrès)

08.30 – 08.45 Welcome and introduction (N. Drager, TBVI)

08.45 – 10.30 Plenary: Progress in TB vaccine product development (Chair: TBC)

- Selected late and mid stage clinical candidates
  - M72 (TBC)
  - VPM1002 (TBC)
  - MTBVAC (I. Murillo, BioFabri)
  - H56 (A. Borges, SSI)
  - RUTI (O. Rue, Archivel)
  - ID93 (R. Coler, IDRI)
  - Others?
- Preclinical approaches
  - RhCMV (TBC)
  - Ready for phase I from TBVAC2020 (A. Rawkins, PHE)

10.30 – 11.00 *Coffee break*

11:00 - 12:00 Plenary: Rational selection and progression of TB vaccine candidates (Chair: TBC)

- Product candidate selection process (B.Patel)
- TB Vaccine Development Pathway, H2H comparison, back-translation (TBC)
- Pathways to licensure and implementation (J. Vekemans, WHO; and F. Cobelens, AIGHD and TBC)

12.00 – 13.15 *Lunch* (Restaurant Eurotel)

- 13:15 - 18:00 Moderated workshops: Current considerations in TB vaccine development (Chair: TBC)
- Emerging immune correlates and biomarkers (T. Ottenhoff, LUMC; B. Javid, TUSM)
  - Controlled Human Infection model (H. McShane, UOx; and TBC)

15:00-15:30 *Coffee break*

- Clinical development and novel clinical trial designs (M. Hatherill, SATVI, and TBC)
- Whole cell vaccines (TBC)
- Discussion of workshop conclusions (session chair)

19.00 *Dinner (restaurant Eurotel)*

## **Wednesday 29 January 2020**

(Maison des Congrès)

08:30 - 12:00 Keynotes and short presentations of current research: Discovery and translation into lead candidates (Chair: W. Hanekom, AHRI)

- Immunological mechanisms of protection (S. Stenger, UKU)
- Innovative vaccine technologies and antigens (TBC)

10:30 - 11:00 *Coffee break*

- Progress in preclinical models (F. Verreck, BPRC)

12:00 - 13:15 *Lunch (restaurant Eurotel)*

13:15 - 15:00 Plenary: Current and future global TB vaccine R&D to maintain and diversify the pipeline  
(Chair: G. Voss, TBVI)

- TBVAC2020 final results (TBC)
- CTVD Research Communities (TBC)
- NIH IMPAc-TB projects (TBC)
- European TB vaccine priorities for Horizon Europe (TBC)
- Synergies with other global health initiatives (R. Tatoud, IAS)
- Overall conclusions (session chair)

15:00-15:30 *Coffee break*

15:30-18:00 Side meetings

- Progress in EDCTP-funded clinical development
- R&I group meeting to discuss conclusions from conference
- GTBVP meeting
- P&CDT meeting

19.00 *Dinner (restaurant Eurotel)*